MS4A4A-MS4A6A Cooperation in TREM2 Regulation

MS4A4A-MS4A6A Cooperation in TREM2 Regulation

Introduction

The [MS4A4A](/genes/ms4a4a) and [MS4A6A](/genes/ms4a6a) genes, located in the MS4A gene cluster on chromosome 11q12, have emerged as significant [Alzheimer's disease](/diseases/alzheimers-disease) risk genes through genome-wide association studies. A groundbreaking 2026 study published in Neuron revealed that these two genes cooperate to negatively regulate [TREM2](/proteins/trem2), a critical receptor on [microglia](/cell-types/microglia-neuroinflammation) that mediates amyloid clearance and inflammatory responses.[@rosner2026] This cooperative regulatory mechanism represents a novel therapeutic target for AD intervention.

Overview

The discovery that [MS4A4A](/genes/ms4a4a) and [MS4A6A](/genes/ms4a6a) cooperate to regulate TREM2 builds upon earlier findings showing that:

Genetic variants in the MS4A gene cluster influence AD risk

MS4A4A interacts with TREM2 as a functional receptor complex[@berger2019]

MS4A4A expression affects microglial function and amyloid clearance[@juric2019]

The new study demonstrates that while MS4A4A and TREM2 can form a direct complex, the primary mechanism of MS4A4A's effect on TREM2 is indirect—mediated through MS4A6A and the DAP12 co-receptor.

Genetic Architecture of the MS4A Locus

Gene Cluster Organization

The MS4A gene cluster on chromosome 11q12.2 contains multiple genes including:

...

MS4A4A-MS4A6A Cooperation in TREM2 Regulation

Introduction

The [MS4A4A](/genes/ms4a4a) and [MS4A6A](/genes/ms4a6a) genes, located in the MS4A gene cluster on chromosome 11q12, have emerged as significant [Alzheimer's disease](/diseases/alzheimers-disease) risk genes through genome-wide association studies. A groundbreaking 2026 study published in Neuron revealed that these two genes cooperate to negatively regulate [TREM2](/proteins/trem2), a critical receptor on [microglia](/cell-types/microglia-neuroinflammation) that mediates amyloid clearance and inflammatory responses.[@rosner2026] This cooperative regulatory mechanism represents a novel therapeutic target for AD intervention.

Overview

The discovery that [MS4A4A](/genes/ms4a4a) and [MS4A6A](/genes/ms4a6a) cooperate to regulate TREM2 builds upon earlier findings showing that:

Genetic variants in the MS4A gene cluster influence AD risk

MS4A4A interacts with TREM2 as a functional receptor complex[@berger2019]

MS4A4A expression affects microglial function and amyloid clearance[@juric2019]

The new study demonstrates that while MS4A4A and TREM2 can form a direct complex, the primary mechanism of MS4A4A's effect on TREM2 is indirect—mediated through MS4A6A and the DAP12 co-receptor.

Genetic Architecture of the MS4A Locus

Gene Cluster Organization

The MS4A gene cluster on chromosome 11q12.2 contains multiple genes including:

| Gene | Position | Expression | AD Association |
|------|----------|------------|----------------|
| [MS4A4A](/genes/ms4a4a) | 11q12.2 | Microglia | Risk gene |
| [MS4A6A](/genes/ms4a6a) | 11q12.2 | Microglia | Risk gene |
| MS4A7 | 11q12.2 | Low | Some association |
| MS4A2 | 11q12.2 | Mast cells | No AD link |

AD Risk Variants

Multiple GWAS-identified variants in this locus affect:

• CSF soluble TREM2 (sTREM2) levels
• Microglial activation states
• Disease progression and risk

Mechanistic Pathway

Step-by-Step Mechanism

Molecular Interactions

MS4A4A-MS4A6A Interaction

MS4A4A protects MS4A6A from degradation

Stabilized MS4A6A can form complexes

This is the key regulatory step

MS4A6A-DAP12 Interaction

MS4A6A binds to DAP12 (TYROBP)

DAP12 normally co-receptors with TREM2

MS4A6A competes for DAP12 availability

Results in reduced TREM2-DAP12 signaling

Downstream Effects

When TREM2-DAP12 signaling is reduced:

• Phagocytosis impaired (reduced Aβ clearance)
• Microglial viability decreased
• Lysosomal function compromised
• Inflammatory response dysregulated

Evidence from the Study

Experimental Approaches

The 2026 Neuron paper used multiple approaches:

Knockout models: MS4A4A and MS4A6A genetic deletion

Overexpression studies: Increased expression to test effects

Degrading antibodies: Protein clearance to assess function

Multiple species: Macrophages, microglia, non-human primates, mice

Key Findings

| Finding | Species | Implication |
|---------|---------|-------------|
| MS4A4A stabilizes MS4A6A | Human/mouse | Key regulatory step |
| MS4A6A blocks DAP12 | Cell culture | Competitive inhibition |
| Knockout increases TREM2 | Mouse models | Negative regulation confirmed |
| Overexpression reduces TREM2 | Multiple systems | Dose-dependent effect |

Comparison with Direct TREM2-MS4A4A Interaction

Earlier Findings

Prior research established that MS4A4A can directly interact with TREM2:

• Direct protein-protein binding on microglial surface
• Co-clustering in lipid rafts
• Cooperative signaling in phagocytosis
• Regulation of microglial survival pathways

The 2026 Discovery

The new study shows:

• The dominant effect of MS4A4A on TREM2 is indirect
• MS4A4A's primary role is protecting MS4A6A
• MS4A6A then blocks DAP12 from TREM2
• This represents a two-step regulatory pathway

Therapeutic Implications

| Approach | Target | Strategy |
|----------|--------|----------|
| MS4A4A inhibition | Increase TREM2 | Enhance phagocytosis |
| MS4A6A inhibition | Increase TREM2 | Enhance phagocytosis |
| MS4A4A-MSA6A disruptor | Block interaction | Release TREM2 |
| Direct TREM2 agonist | Bypass regulation | Activate signaling |

Microglial States Affected

Homeostatic Microglia

• TREM2 required for transition to activated states
• MS4A4A/MS4A6A negatively regulate this transition

Disease-Associated Microglia (DAM)

• TREM2-dependent activation
• MS4A4A/MS4A6A limit DAM formation and function

Specific Effects

| Microglial Function | Effect of MS4A4A/MS4A6A |
|---------------------|-------------------------|
| Viability | Reduced |
| Phagocytosis | Impaired |
| Lysosomal function | Compromised |
| Metabolic fitness | Decreased |
| Inflammatory response | Dysregulated |

Comparison with TREM2 Variants

TREM2 Loss-of-Function Variants

Rare variants in TREM2 (R47H, R62H, Y38C) cause:

• ~2-4x increased AD risk
• Impaired ligand binding
• Reduced phagocytosis
• Similar phenotype to MS4A4A/MS4A6A overexpression

MS4A4A/MS4A6A Effect

• Genetic variants increase AD risk
• Mechanism: reduced TREM2 signaling
• Phenotype: similar to TREM2 LOF variants
• Potential for therapeutic modulation

Therapeutic Implications

Targeting Strategy

The MS4A4A-MS4A6A-TREM2 axis offers multiple intervention points:

Advantages of MS4A4A/MS4A6A Targeting

Upstream intervention: Modulate before TREM2

Combination potential: Can pair with TREM2 agonists

Cell-type specificity: Microglia-expressed

Genetic validation: GWAS-confirmed AD risk genes

Challenges

Balancing act: Too much TREM2 activation may cause inflammation

Timing: Early vs. late-stage intervention

Specificity: Targeting the right gene/products

Delivery: Brain penetration requirements

MS4A Gene Family Evolution

Gene Family Overview

The MS4A gene family has undergone significant expansion in humans compared to other mammals. The cluster on chromosome 11q12.2 contains at least 10 MS4A genes in humans, many of which show brain-specific or immune cell expression. This expansion coincided with increased complexity of microglial regulation in primate brains.

Expression Patterns

| Gene | Brain Expression | Immune Cell Expression | Tissue Distribution |
|------|-----------------|------------------------|-------------------|
| MS4A4A | High | Microglia-specific | Brain, spinal cord |
| MS4A6A | High | Microglia-specific | Brain |
| MS4A7 | Low | Some | Lung, spleen |
| MS4A2 | Very low | Mast cells | Various |

Evolutionary Conservation

MS4A4A and MS4A6A show conservation across mammalian species, with orthologous genes in mice, rats, and non-human primates. However, regulatory elements and splicing patterns show species-specific differences. This has implications for translational research using mouse models.

Molecular Structure of MS4A Proteins

Protein Architecture

MS4A proteins are typical 4-transmembrane domain proteins with extracellular loops and intracellular termini. The structure includes:

• N-terminal cytoplasmic domain: Contains potential phosphorylation sites
• Extracellular loop 1: Variable region involved in ligand binding
• Transmembrane domains: Four alpha-helices anchoring the protein
• Extracellular loop 2: Larger loop with potential protein interaction sites
• C-terminal cytoplasmic domain: Contains motifs for signaling

Post-Translational Modifications

MS4A4A and MS4A6A undergo several post-translational modifications:

• N-glycosylation: In extracellular domains
• Phosphorylation: In cytoplasmic domains
• Palmitoylation: For membrane association
• Dimerization: For functional complex formation

TREM2 Signaling Cascade

Downstream Signaling Pathways

TREM2 signaling through DAP12 initiates multiple downstream cascades:

Cellular Responses

TREM2 activation regulates multiple microglial functions:

| Function | TREM2 Effect | MS4A4A/MS4A6A Effect |
|----------|-------------|---------------------|
| Phagocytosis | ↑ Strong | ↓ Via TREM2 reduction |
| Cell survival | ↑ Pro-survival | ↓ Via TREM2 reduction |
| Metabolic fitness | ↑ Enhanced | ↓ Via TREM2 reduction |
| Cytokine production | Modulated | Altered pattern |
| Migration | ↑ Chemotaxis | ↓ Reduced |

MS4A4A-MS4A6A in Disease Context

Alzheimer's Disease Progression

The MS4A4A-MS4A6A-TREM2 axis operates differently across AD stages:

Early Stage:

• MS4A4A/MS4A6A expression may be protective
• Negative regulation limits excessive inflammation
• TREM2 activation promotes amyloid clearance

Moderate Stage:

• Regulated TREM2 becomes insufficient
• Microglial activation states shift
• Amyloid clearance becomes impaired

Late Stage:

• Chronic dysregulation contributes to neuroinflammation
• TREM2-dependent functions decline
• Neurodegeneration accelerates

Other Neurodegenerative Diseases

The MS4A4A-MS4A6A axis may have relevance beyond AD:

Parkinson's Disease:

• Microglial involvement in PD pathogenesis
• TREM2 variants may affect risk
• Potential for therapeutic modulation

ALS:

• Microglial contribution to disease
• TREM2 in inflammatory responses
• MS4A gene involvement uncertain

FTD:

• TREM2 variants in FTD risk
• MS4A genes less studied
• Potential mechanistic overlap

Therapeutic Development

Antibody Approaches

MS4A4A Antagonist Antibodies

• Block MS4A4A stabilization of MS4A6A
• Increase available DAP12 for TREM2
• Enhance TREM2 signaling indirectly
• Requires brain penetration

MS4A6A Blocking Antibodies

• Prevent DAP12 sequestration
• Free DAP12 for TREM2
• Direct mechanism
• May have fewer off-target effects

TREM2 Agonist Antibodies

• Direct activation of TREM2
• Bypass MS4A regulation
• Currently in clinical development
• Potential combination with MS4A targeting

Small Molecule Inhibitors

Targeting MS4A4A-MS4A6A interaction:

• Interface blockers: Disrupt protein-protein binding
• Degraders: Promote MS4A6A degradation
• Expression inhibitors: Reduce MS4A transcription

Gene Therapy Approaches

• CRISPR editing to correct risk variants
• siRNA to reduce MS4A expression
• AAV delivery to microglia

Biomarker Considerations

Treatment Response Markers:

• CSF sTREM2 levels
• Microglial activation markers
• Amyloid PET changes
• Cognitive measures

Patient Selection:

• MS4A genotypes
• TREM2 variant status
• Disease stage
• Amyloid burden

Research Challenges

Species Differences

Key challenges in translating findings:

| Aspect | Human | Mouse | Implication |
|--------|-------|-------|-------------|
| Gene cluster | 10+ genes | ~6 genes | Different regulation |
| Expression | Microglia-high | Mixed | Translation |
| Protein sequence | 80% identical | ~80% | Function conserved |
| Response to injury | Complex | Simplified | Model limitations |

Technical Considerations

Measuring Function:

• MS4A4A-MS4A6A interaction assays
• TREM2 signaling readouts
• Microglial functional assays
• In vivo imaging

Model Limitations:

• Cell line models oversimplify
• Primary cells limited
• Animal models incomplete
• Cross-species differences

Future Directions

Unanswered Questions

What determines the balance between beneficial and harmful MS4A4A/MS4A6A effects?

How do MS4A4A and MS4A6A variants affect disease progression?

Can timing of intervention improve outcomes?

What combination approaches will be most effective?

Clinical Translation Priorities

Develop biomarkers for patient selection

Establish optimal treatment windows

Determine combination therapy approaches

Monitor treatment response

Cross-Links

• [MS4A4A Gene](/genes/ms4a4a)
• [MS4A6A Gene](/genes/ms4a6a)
• [TREM2 Gene](/genes/trem2)
• [TREM2 Protein](/proteins/trem2)
• [TREM2 Microglia Pathway](/mechanisms/trem2-microglia-pathway-alzheimers)
• [Microglia](/cell-types/microglia-neuroinflammation)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Disease-Associated Microglia](/mechanisms/disease-associated-microglia)
• [Microglial Phagocytosis](/mechanisms/microglial-phagocytosis)
• [DAP12/TYROBP Pathway](/mechanisms/tyrobp-dap12-microglia-pathway)

References

[Rosner et al., The Alzheimer's disease risk genes MS4A4A and MS4A6A cooperate to negatively regulate TREM2 and microglia states (2026)](https://pubmed.ncbi.nlm.nih.gov/41435829/)

[Juric et al., Microglial MS4A4A modulates TREM2 signaling and AD risk (2019)](https://pubmed.ncbi.nlm.nih.gov/31152062/)

[Berger et al., MS4A4A and TREM2 form a functional receptor complex on microglia (2019)](https://pubmed.ncbi.nlm.nih.gov/31400156/)

[Chen et al., The MS4A gene cluster as a modulator of Alzheimer's disease risk (2020)](https://pubmed.ncbi.nlm.nih.gov/33077947/)